RxDoctor Payments Data

Jorge Barboza-Sosa, MD

Internal Medicine · Eagle Pass, TXNPI 1437203437

Payments from drug & device makers

$3,289in general payments, 2019–2025

Across 159 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$810
  • Johnson & Johnson$298
  • Lilly USA, LLC$168
  • Novartis$160
  • Amarin Pharma, Inc.$146
  • plus $420 from 11 others

What the payments were for

  • Food & beverage$3,289100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,289 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$149,474
Medicare patients
311
Services billed
1,692

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate297$281,636
LinzessLinaclotide125$147,903
EliquisApixaban125$137,619
RybelsusSemaglutide69$132,887
OzempicSemaglutide80$94,477
FarxigaDapagliflozin Propanediol83$93,029
XifaxanRifaximin38$78,755
XareltoRivaroxaban108$73,215
JardianceEmpagliflozin38$62,554
JanumetSitagliptin Phos/Metformin Hcl54$60,234
TradjentaLinagliptin57$51,384
MyrbetriqMirabegron67$35,403
Janumet XrSitagliptin Phos/Metformin Hcl21$31,268
EntrestoSacubitril/Valsartan16$28,301
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$22,384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$119$373,138372 claims
Novo NordiskRybelsus, Ozempic$810$227,364149 claims
AbbVieLinzess, Lumigan$36$151,897139 claims
PfizerEliquis$38$137,619125 claims
AstraZenecaFarxiga, Symbicort$1,288$97,03096 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$12$78,75538 claims
Johnson & JohnsonXarelto$298$73,215108 claims
NovartisEntresto$160$28,30116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Eagle Pass

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →